Clinical trial · Interventional
Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy
A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer
NCT00380965CI-TRIAL-00001155completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to chemotherapy-induced neuropathic pain in patients with cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Antineoplastic Combined Chemotherapy Protocols | — | UNRESOLVED | — |
| Peripheral Neuropathy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cesamet™ (nabilone) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The Average Pain Score at target site.
Secondary outcomes (5)
- measure
- The Worst Pain Score at target site.
- measure
- The Pain at Night Score at target site.
- measure
- Quality of Life measures.
- measure
- Patient satisfaction with treatment.
- measure
- Safety will be assessed through the collection of AEs and vital signs.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with chemotherapy-induced neuropathic pain. * Chronic daily pain present for at least 2 months. * On stable analgesic regimen for one month. * Baseline pain score greater than 40mm on a VAS. Exclusion Criteria: * Hypersensitivity to compounds in study drug or similar drugs * Pregnant or lactating females * Drug or alcohol abuse * Unstable medical condition
References
Publications (0)
Data not yet available
No reference posted for this study.